Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
R228060 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| R228060 | DRUG | - |
| Placebo and Paroxetine | DRUG | - |
* Generally healthy adults on the basis of a physical examination, medical history, ECG and laboratory work-up. * Subject needs to meet criteria for diagnosis of moderate or severe major depression as defined by the protocol. * The subject also needs to be an outpatient to participate in this study.
Top 20 of 29 competitors
R228060 is an investigational small molecule being studied for the treatment of Major Depressive Disorder in adults. It is currently in Phase 2 clinical development and is not approved by the FDA. A completed Phase 2 trial evaluated its effectiveness in adult subjects with Major Depressive Disorder.
R228060 is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker symbol JNJ. The drug is an investigational small molecule in Phase 2 clinical development for Major Depressive Disorder.
R228060 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 2 trial for the drug has been completed, and the drug is not currently in any active clinical trials.
R228060 has one completed Phase 2 clinical trial, identified as NCT00073203. This was a 6-week study to determine the effectiveness of R228060 in adult subjects with Major Depressive Disorder. The trial enrolled 488 participants in the United States and was randomized and double-blind.
No, R228060 is not FDA approved. It is an investigational small molecule currently in Phase 2 clinical development for Major Depressive Disorder. The drug has completed one Phase 2 trial but has not yet received regulatory approval.